OBJECTIVE: The objective of this study was to determine current practices of anticoagulation in patients on extracorporeal membrane oxygenation. DESIGN: Internet-based cross-sectional survey distributed between November 2010 and May 2011. SETTING: Extracorporeal Life Support Organization-registered extracorporeal membrane oxygenation centers internationally. PARTICIPANTS: : Extracorporeal membrane oxy genation medical directors and coordinators. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: There were 121 responses from extracorporeal membrane oxy genation medical directors and coordinators at 187 Extracorporeal Life Support Organization centers with access to the survey. Eighty-four of 117 (72%) respondents reported having a written institutional extracorporeal membrane oxy genation protocol for both anticoagulation and blood product management at their institutions. Sixty-nine of 117 (59%) respondents reported use of tip-to-tip or partially heparin-bonded circuits. Unfractionated heparin was used at all centers; only 8% of respondents indicated use of alternative anticoagulation medications in the six months prior to the survey. The preferred method of anticoagulation monitoring was the serial measurement of activated clotting time, as reported by 97% of respondents. In this survey, 82% of respondents reported antithrombin III testing, 65% reported anti-factor Xa testing, and 43% reported use of thromboelastography during extracorporeal membrane oxy genation. Goal ranges for these three tests and interventions triggered by out-of-range values were found to be variable. CONCLUSIONS: Extracorporeal membrane oxy genation anticoagulation management policies vary widely by center. The majority of extracorporeal membrane oxy genation programs employ activated clotting time as the preferred anticoagulation monitoring tool. The coagulation system is also monitored using more specific markers such as antithrombin III, anti-factor Xa, and thromboelastography by a large number of centers. Future research is needed to elucidate optimal anticoagulation management and improve outcomes.
OBJECTIVE: The objective of this study was to determine current practices of anticoagulation in patients on extracorporeal membrane oxygenation. DESIGN: Internet-based cross-sectional survey distributed between November 2010 and May 2011. SETTING: Extracorporeal Life Support Organization-registered extracorporeal membrane oxygenation centers internationally. PARTICIPANTS: : Extracorporeal membrane oxy genation medical directors and coordinators. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: There were 121 responses from extracorporeal membrane oxy genation medical directors and coordinators at 187 Extracorporeal Life Support Organization centers with access to the survey. Eighty-four of 117 (72%) respondents reported having a written institutional extracorporeal membrane oxy genation protocol for both anticoagulation and blood product management at their institutions. Sixty-nine of 117 (59%) respondents reported use of tip-to-tip or partially heparin-bonded circuits. Unfractionated heparin was used at all centers; only 8% of respondents indicated use of alternative anticoagulation medications in the six months prior to the survey. The preferred method of anticoagulation monitoring was the serial measurement of activated clotting time, as reported by 97% of respondents. In this survey, 82% of respondents reported antithrombin III testing, 65% reported anti-factor Xa testing, and 43% reported use of thromboelastography during extracorporeal membrane oxy genation. Goal ranges for these three tests and interventions triggered by out-of-range values were found to be variable. CONCLUSIONS: Extracorporeal membrane oxy genation anticoagulation management policies vary widely by center. The majority of extracorporeal membrane oxy genation programs employ activated clotting time as the preferred anticoagulation monitoring tool. The coagulation system is also monitored using more specific markers such as antithrombin III, anti-factor Xa, and thromboelastography by a large number of centers. Future research is needed to elucidate optimal anticoagulation management and improve outcomes.
Authors: Christopher E Colby; Arlene Sheehan; William Benitz; Krisa Van Meurs; Louis P Halamek; R Lawrence Moss Journal: J Extra Corpor Technol Date: 2003-03
Authors: B L Warren; A Eid; P Singer; S S Pillay; P Carl; I Novak; P Chalupa; A Atherstone; I Pénzes; A Kübler; S Knaub; H O Keinecke; H Heinrichs; F Schindel; M Juers; R C Bone; S M Opal Journal: JAMA Date: 2001-10-17 Impact factor: 56.272
Authors: William C Oliver; Froukje M Beynen; Gregory A Nuttall; Darrell R Schroeder; Mark H Ereth; Joseph A Dearani; Francisco J Puga Journal: Ann Thorac Surg Date: 2003-05 Impact factor: 4.330
Authors: Andreas Koster; George Despotis; Marcus Gruendel; Thomas Fischer; Michael Praus; Herman Kuppe; Jerrold H Levy Journal: Anesth Analg Date: 2002-07 Impact factor: 5.108
Authors: David K Werho; Sara K Pasquali; Sunkyung Yu; Janet Donohue; Gail M Annich; Ravi R Thiagarajan; Jennifer C Hirsch-Romano; Michael Gaies Journal: Ann Thorac Surg Date: 2015-08-20 Impact factor: 4.330
Authors: Jason P Sulkowski; Thomas J Preston; Jennifer N Cooper; Victoria L Duffy; Katherine J Deans; Louis G Chicoine; Peter C Minneci Journal: J Extra Corpor Technol Date: 2014-03
Authors: Jacob T Beyer; Kelly E Schoeppler; Giorgio Zanotti; Gregory M Weiss; Scott W Mueller; Robert MacLaren; Douglas N Fish; Tyree H Kiser Journal: Clin Appl Thromb Hemost Date: 2016-09-13 Impact factor: 2.389
Authors: Jane Yu; Elizabeth Brisbois; Hitesh Handa; Gail Annich; Mark Meyerhoff; Robert Bartlett; Terry Major Journal: J Mater Chem B Date: 2016-03-01 Impact factor: 6.331